From Breakthrough Science to Clinical Reality
Advancing MultiPlex innovation approaches in oncology
Our development pipeline is focused on innovative approaches to cancer with high potential to deliver meaningful patient results.
Lead Programs
MultiPlex In Vivo CAR-T
The Vision: Transform CAR-T from complex manufacturing to simple injection while enabling dual-target and enhanced approaches to drive clinical efficacy.
Clinical Foundation: Recent clinical data show that dual-CAR constructs can achieve higher responses in patients. However, current in vivo approaches are limited in their ability to deliver complex designs.
Chimeron's Breakthrough: Chimeron’s MultiPlex platform achieves long-lasting expression in T cells and uniquely enables in vivo delivery of enhanced dual-CAR and CAR-plus constructs engineered for more effective T-cell engagement.
Immuno-oncology
Vision: Transform patient's tumor immune microenviorment to drive immune surveillance and elimination of cancer cells.
- MultiPlex gene delivery and coordinated expression targeting multiple immune pathways
- Weeks-long therapeutic activity
- Precise targeting with enhanced uptake
Clinical Foundation: Recent clinical validation shows that intratumoral delivered therapies demonstrated activity not only within the treated tumor but also in untreated distal tumors, highlighting the potential for systemic immune engagement.
Chimeron's Breakthrough: Novel multiplex combination immunotherapy, expressed for weeks rather than days, driving potent and durable anti-tumor responses.
Our versatile and unique platform also extends its potential applications
to cancer vaccines, infectious diseases, genetic disorders and gene therapies.